Schilke Tobin's Form 4 filing
Revance Therapeutics, Inc. (RVNC) · filed Jan 10, 2023
- Accession no.
- 0001479290-23-000007
- Filed
- Jan 10, 2023
- Trade date
- Jan 9, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $100.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schilke TobinCIK 0001678984 | Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2023 | Common Stock | SSaleDisposed | −1,701 | $25.00 | −$42,525 | 60,877 | Direct | |
| Jan 9, 2023 | Common Stock | SSaleDisposed | −1,000 | $28.00 | −$28,000 | 59,877 | Direct | |
| Jan 9, 2023 | Common Stock | SSaleDisposed | −1,000 | $30.00 | −$30,000 | 58,877 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.